Intensity Therapeutics, Inc..
INTS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel drug candidates designed to kill tumors and induce sustained anti-tumor immunity. Their lead product candidate, INT230-6, is designed for direct intratumoral injectio...Show More
Better Health for All
-20
Intensity Therapeutics' lead product candidate, INT230-6, is a cancer therapy demonstrating significant positive health impacts. Clinical trials show up to 95% tumor necrosis, disease control rates of 75% (83.3% for optimal dosing), and improved median overall survival of 11.9 months (18.7 months for optimal dosing) in heavily pretreated patients.
1
The drug also induces immune responses and abscopal effects, with approximately 20% of patients experiencing shrinkage of uninjected tumors.
2
The company's entire focus and financial resources are dedicated to developing this product, having raised $54.5 million since inception and holding 15 issued patents.
3
Safety data from the IT-01 study showed 10.9% of 64 monotherapy patients experienced Grade 3 treatment-related adverse events, with no Grade 4 or 5 events.
4
In the INVINCIBLE-4 study, patients receiving INT230-6 plus standard of care experienced nine Grade 3 or higher adverse events, compared to 20 in the standard chemotherapy group.
5
However, the company's annual report included an explanatory paragraph indicating substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows.
6
The company also paused new patient enrollment in the INVINCIBLE-4 study to address localized skin irritation and observed tissue necrosis in some patients, implementing protocol changes.
7
The company's orphan drug designation for soft tissue sarcoma grants seven years of marketing exclusivity.
8
Fair Money & Economic Opportunity
0
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on drug discovery and development. The provided articles detail its clinical trials, financial results, and product development. There is no evidence that the company engages in financial services such as lending, offering deposit services, managing customer financial data, or providing financial literacy programs. Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are scored as 'Not applicable' as the company's core business lies outside the financial sector.
Fair Pay & Worker Respect
0
No evidence available to assess Intensity Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, quantitative data points were found in the provided articles to assess Intensity Therapeutics, Inc. against any of the Fair Trade & Ethical Sourcing KPIs.
1
The articles either explicitly state a lack of relevant data or discuss general industry principles without company-specific metrics for the company.
2
Honest & Fair Business
-50
Intensity Therapeutics has a Whistleblower Policy that outlines the process for filing anonymous complaints and prohibits retaliation against employees reporting violations.
1
The company reported a reclassification of $81,781 and $16,767 of interest expense in 2022 and 2021, respectively, which was disclosed in March 2023.
2
The company states it has taken reasonable steps to ensure compliance with the Foreign Corrupt Practices Act of 1977.
3
Financial statements have been audited by EisnerAmper LLP, an independent registered public accounting firm, but the extent of this audit coverage for ethical claims is not specified.
4
Kind to Animals
-60
Intensity Therapeutics, Inc. relies on animal testing, specifically using murine models for preclinical studies of its drug candidate INT230-6.
1
The company's research includes in vivo models of Malignant Peripheral Nerve Sheath Tumor and pancreatic murine tumor xenografts.
2
There is no mention of alternative testing methods being employed.
3
The company conducts preclinical research in neurological cancer models and animal pharmacology testing, and explicitly exploits animals for product testing.
4
In one study, INT230-6 was tested on a group of 5 mice, with a control group also consisting of 5 mice.
5
Another study involved 10,000-15,000 animals annually.
No War, No Weapons
0
No evidence was found in the provided articles to assess Intensity Therapeutics, Inc. against any of the KPIs for the 'No War, No Weapons' ethical value. The company's core business, as described, is clinical-stage biotechnology focused on cancer treatment.
1
The articles provided detail its cancer treatment pipeline and corporate governance, with no information regarding arms contracts, dual-use technology, peacebuilding investments, or any other metrics related to military or conflict-related activities.
2
Planet-Friendly Business
0
The provided articles primarily detail Intensity Therapeutics' financial performance and clinical trial progress. Articles and explicitly state that sustainability data is currently unavailable for INTS.US.
1
Consequently, no specific, concrete data points are available to assess the company against any of the 'Planet-Friendly Business' KPIs.
Respect for Cultures & Communities
0
The company has no reported formal partnerships with indigenous or local community groups.
1
Its listed partnerships are with research institutions and pharmaceutical companies,
2
consistent with its business model as a clinical-stage biotechnology company focused on drug discovery and development.
Safe & Smart Tech
0
The company has reported no material cybersecurity incidents in its 2025 and 2024 filings.
1
It employs technical safeguards such as firewalls, intrusion prevention and detection systems, anti-malware functionality, double verification software, and access controls.
2
The board of directors provides direct oversight over cybersecurity risk and receives periodic updates from management.
3
The company provides mandatory training for its employees regarding cybersecurity threats.
4
It monitors emerging data protection laws and implements changes to processes designed to comply with such laws.
5
The company's privacy policy, last updated in February 2021, states that personal data is retained only as long as necessary for the purposes set out in the policy and to comply with legal obligations.
6
It also states that usage data is used to strengthen security or improve service functionality.
7
Users can instruct their browser to refuse all cookies.
8
Zero Waste & Sustainable Products
0
No specific data is provided for Intensity Therapeutics, Inc. regarding waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging to product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1